Philogen SpA (MIL:PHIL) ROC %: 1,102.65% (As of Dec. 2025)


MIL:PHIL Philogen SpA MIL:PHIL
62 GF Score
Price €23.30
GF Value €227.22
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Philogen SpA ROC %?

Philogen SpA MIL:PHIL +2.19% 62 ROC % is 1,102.65% as of Dec. 2025. GuruFocus rates MIL:PHIL with a GF Score™ of 62/100 and a GF Value™ of €227.22 (Possible Value Trap). The stock has 3 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Philogen SpA's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was 1,102.65%.

As of today (2026-06-26), Philogen SpA's WACC % is 3.33%. Philogen SpA's ROC % is 531.48% (calculated using TTM income statement data). Philogen SpA generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Philogen SpA  (MIL:PHIL) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Philogen SpA's WACC % is 3.33%. Philogen SpA's ROC % is 531.48% (calculated using TTM income statement data). Philogen SpA generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Philogen SpA ROC % Related Terms


Philogen SpA ROC % Historical Data

* Premium members only.

The historical data trend for Philogen SpA's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Philogen SpA ROC % Chart

Philogen SpA Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
Get a 7-Day Free Trial -63.61 2.75 -25.40 102.79 545.24

Philogen SpA Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -90.26 -100.68 301.91 -71.58 1,102.65
MIL:PHIL
62GF Score
Philogen SpA MIL:PHIL
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Philogen SpA ROC % Calculation

Philogen SpA's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=258.101 * ( 1 - 11.7% )/( (40.429 + 43.168)/ 2 )
=227.903183/41.7985
=545.24 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=168.452 - 14.294 - ( 113.729 - max(0, 16.639 - 132.325+113.729))
=40.429

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=437.328 - 47.572 - ( 379.221 - max(0, 51.289 - 397.877+379.221))
=43.168

Philogen SpA's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=547.74 * ( 1 - 11.21% )/( (45.045 + 43.168)/ 2 )
=486.338346/44.1065
=1,102.65 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=159.346 - 16.201 - ( 100.021 - max(0, 20.756 - 118.856+100.021))
=45.045

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=437.328 - 47.572 - ( 379.221 - max(0, 51.289 - 397.877+379.221))
=43.168

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of 1,102.65% mean?
Philogen SpA (MIL:PHIL) has a ROC % of 1,102.65% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Philogen SpA and its competitors.
Is Philogen SpA's ROC % too high?
Philogen SpA's current ROC % is 1,102.65%. Overall, Philogen SpA has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's ROC % compare to VRTX and REGN?
Philogen SpA's ROC % of 1,102.65% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Philogen SpA and its competitors. Philogen SpA's current ROC % is 1,102.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €227.22, compared to a current price of €23.30 — trading 89.7% below its estimated fair value. The current ROC % is 1,102.65%. Philogen SpA's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current ROC % is 1,102.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Philogen SpA (MIL:PHIL) Overvalued in 2026?

Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued. The current stock price of €23.30 is trading 89.7% below its estimated GF Value™ of €227.22. GuruFocus considers Philogen SpA to be Possible Value Trap.

Key valuation signals for MIL:PHIL:

  • ROC %: 1,102.65%
  • GF Value™: €227.22 vs. price of €23.30 (89.7% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Philogen SpA Business Description

Other Exchanges 78Q:Germany
Address Piazza La Lizza No. 7, Siena, ITA, 53100
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
62GF Score

Get the complete analysis for MIL:PHIL

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€23.30
Price
€227.22
GF Value